Eisai Establishes Pharma Sales Subsidiary in Vietnam

Sep 17, 2020 09:59 JST

Source: Eisai

TOKYO, Sep 17, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam (Vietnam), which will be named Eisai Vietnam Co., Ltd. (Eisai Vietnam). Eisai Vietnam is a wholly-owned subsidiary of Eisai.

The pharmaceutical market in Vietnam is surpassed in size only by those of Thailand and the Philippines within the Association of Southeast Asian Nations (ASEAN), with the market size reaching 4,199 million USD in 20191. The compound annual growth rate of the Vietnamese pharmaceutical market from 2014 to 2019 was +10.6%(1), and it is expected that this market rate will continue to grow in the double digits. In 1992, Eisai (Thailand) Marketing Co., Ltd., a pharmaceutical sales subsidiary of Eisai, started business in Vietnam through a local agency. Eisai opened a representative office in Ho Chi Minh City in 1995, and mainly markets the proton-pump inhibitor Pariet, muscle relaxant Myonal, peripheral neuropathy treatment Methycobal, and others.

In addition, regarding its global products in Vietnam, Eisai recently launched its antiepileptic drug Fycompa in October 2019, and obtained marketing approval for the anti-cancer agent Lenvima in June 2020. Eisai has also filed for regulatory approval for the in-house developed anti-cancer agent Halaven.

With the establishment of Eisai Vietnam, Eisai aims to enhance its own drug sales system in Vietnam, deliver innovative new drugs to more patients in Vietnam, and contribute to improving the benefits of patients and their families.

(1) Copyright 2020 IQVIA Created based on IQVIA Analytics Link 2014-2019. Unauthorized reproduction prohibited.

Contact:

Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy

February 16 2026 13:03 JST

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China

February 10 2026 12:34 JST

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

February 06 2026 10:31 JST

FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

January 26 2026 10:37 JST

Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time

January 21 2026 15:44 JST

Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan

January 13 2026 08:50 JST

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

January 06 2026 09:43 JST

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

December 11 2025 18:41 JST

"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

December 09 2025 17:51 JST

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025

December 04 2025 17:36 JST

More Press release >>

Latest Press Release

Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM
Feb 26, 2026 12:30 JST

Toyota Launches New bZ4X Touring BEV Focused on Driving Performance and Spaciousness in Japan
Feb 25, 2026 21:58 JST

DOCOMO and Keio University Demonstrate World's First Stable, High-Fidelity Robot Teleoperation via Commercial 5G Using Low-Latency Slicing
Feb 25, 2026 21:01 JST

DOCOMO Successfully Demonstrates AI Application Operation Using Virtualized Radio Access Network (vRAN) Infrastructure

Feb 25, 2026 20:50 JST

DOCOMO Begins Commercial Deployment of Agentic AI System for Network Maintenance Using One of the World's Largest Datasets
Feb 25, 2026 20:40 JST

NEC Implements AI Code Review Service "Metabob," Reducing Technical Verification Time by Up to 66%
Feb 25, 2026 18:00 JST

Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution
Feb 25, 2026 12:00 JST

Hong Kong Tech Delegation Heading for Market Expansion at Mobile World Congress 2026
Feb 25, 2026 07:00 JST

Galaxy Payroll Group Renews Five-Year Strategic Cooperation Agreement with NIKE China Holding HK Limited (Macau Branch)
Feb 25, 2026 04:35 JST

TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
Feb 24, 2026 22:00 JST

Mitsubishi Shipbuilding Ships First Units of Systems for Marine Ammonia-Fueled Engines

Feb 24, 2026 20:07 JST

MHI Unveils "DIAVAULT," a Secure, High Performance Edge Data Center Platform
Feb 24, 2026 19:55 JST

Fujitsu expands Uvance for Finance offerings to accelerate DX across financial sector
Feb 24, 2026 11:23 JST

MHI Thermal Systems Establishes Local Subsidiary in India and Starts Operations
Feb 24, 2026 11:02 JST

Full Convertible Bond Conversion Removes Overhang and Signals Valuation Reassessment for Shoucheng Holdings
Feb 20, 2026 20:32 JST

Investee Companies Take the National Stage: Shoucheng Holdings' 'Capital+Scenario+Industry Chain' Strategy Validated, Entering the Value Realization Phase
Feb 20, 2026 20:06 JST

Hitachi Rail Invests C$30 Million in New Canadian Headquarters
Feb 20, 2026 12:20 JST

Toyota Launches New RAV4 (PHEV) in Japan
Feb 19, 2026 19:25 JST

Osaka Hospital launches project to safely utilize generative AI for healthcare workforce improvements
Feb 19, 2026 12:12 JST

MHI Machinery Systems Participates in Ramp Merging Support Demonstration Experiment for Autonomous Vehicles on the Tokyo Metropolitan Expressway
Feb 18, 2026 15:37 JST

More Latest Release >>